Medicinal Insights Into FLT3 Inhibitors as Anticancer Agents: Current Status and Future Direction

Area of Science:

• Oncology
• Molecular Biology
• Medicinal Chemistry

Background:

• FMS-like tyrosine kinase 3 (FLT3) is crucial for hematopoietic stem cell function.
• Mutated FLT3, particularly internal tandem duplications (ITD) and tyrosine kinase domain (TKD) mutations, drives acute myeloid leukemia (AML) pathogenesis.
• FLT3 signaling pathways include RAS/MAPK, PI3K/AKT, and STAT5.

Purpose of the Study:

• To review recent advancements in FLT3-targeted therapies for AML.
• To explore diverse chemical scaffolds and structure-activity relationships of FLT3 inhibitors.
• To discuss challenges like resistance and future directions in FLT3-targeted treatment.

Main Methods:

• Comprehensive literature review of FLT3 inhibitors and their clinical applications.
• Analysis of structure-activity relationships (SAR) for various chemical scaffolds.
• Inclusion of molecular docking studies and computational insights.

Main Results:

• Second-generation FLT3 inhibitors like gilteritinib and quizartinib demonstrate improved efficacy and selectivity.
• Quizartinib received FDA approval in 2023 for FLT3-ITD-positive AML.
• Ongoing trials explore novel compounds and combination regimens, showing enhanced remission rates.

Conclusions:

• FLT3-targeted therapies have significantly advanced AML treatment, with ongoing research into novel inhibitors and combinations.
• Overcoming resistance mechanisms, including secondary mutations and pathway activation, is critical for durable responses.
• Future strategies involve structure-guided design, rational combinations, and expanding FLT3 inhibitor applications to other malignancies.